Su Haiyang, Song Yuanlin, Yang Shouzhi, Zhang Ziyue, Shen Yao, Yu Lan, Chen Shujing, Gao Lei, Chen Cuicui, Hou Dongni, Wei Xinping, Ma Xuedong, Huang Pengyu, Sun Dejun, Zhou Jian, Qian Kun
State Key Laboratory of Systems Medicine for Cancer, School of Biomedical Engineering, Institute of Medical Robotics and Med-X Research Institute, Shanghai Jiao Tong University, Shanghai 200030, P. R. China.
Department of Pulmonary and Critical Care Medicine, Shanghai Respiratory Research Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.
ACS Cent Sci. 2024 Jan 27;10(2):331-343. doi: 10.1021/acscentsci.3c01201. eCollection 2024 Feb 28.
Accurate diagnosis of chronic obstructive pulmonary disease (COPD) and exacerbations by metabolic biomarkers enables individualized treatment. Advanced metabolic detection platforms rely on designed materials. Here, we design mesoporous PdPt alloys to characterize metabolic fingerprints for diagnosing COPD and exacerbations. As a result, the optimized PdPt alloys enable the acquisition of metabolic fingerprints within seconds, requiring only 0.5 μL of native plasma by laser desorption/ionization mass spectrometry owing to the enhanced electric field, photothermal conversion, and photocurrent response. Machine learning decodes metabolic profiles acquired from 431 individuals, achieving a precise diagnosis of COPD with an area under the curve (AUC) of 0.904 and an accurate distinction between stable COPD and acute exacerbations of COPD (AECOPD) with an AUC of 0.951. Notably, eight metabolic biomarkers identified accurately discriminate AECOPD from stable COPD while providing valuable information on disease progress. Our platform will offer an advanced nanoplatform for the management of COPD, complementing standard clinical techniques.
通过代谢生物标志物准确诊断慢性阻塞性肺疾病（COPD）及其急性加重期，有助于实现个体化治疗。先进的代谢检测平台依赖于设计的材料。在此，我们设计了介孔钯铂合金来表征用于诊断COPD及其急性加重期的代谢指纹图谱。结果，优化后的钯铂合金能够在数秒内获取代谢指纹图谱，由于增强的电场、光热转换和光电流响应，通过激光解吸/电离质谱仅需0.5微升天然血浆即可实现。机器学习对从431名个体获得的代谢谱进行解码，实现了对COPD的精确诊断，曲线下面积（AUC）为0.904，并且能够准确区分稳定期COPD和慢性阻塞性肺疾病急性加重期（AECOPD），AUC为0.951。值得注意的是，准确鉴定出的八种代谢生物标志物能够准确区分AECOPD和稳定期COPD，同时提供有关疾病进展的有价值信息。我们的平台将为COPD的管理提供一个先进的纳米平台，作为标准临床技术的补充。
